The RESPLASH Study

Starting soon · Not applicable

Conditions studied: Resistant Hypertension

In brief

To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.

Key facts

Study ID: NCT06880562
Run by: Tulane University
People needed: 20
Starts: 2026-06-01
Expected to finish: 2027-06-01
Last updated by the study team: 2026-03-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients aged 18-75.
History of Type 2 Diabetes Mellitus at least 5 years prior to enrollment.
HbA1c level ≥6.5%
Use of at least 1 oral antidiabetic agent and no changes in the last 30 days.
History of essential hypertension with systolic Blood pressure of 160 mmHg or more (≥150 mmHg in patient with Type 2 Diabetes Mellitus), despite compliance with three of more antihypertensive drugs.
Stable drug regimen of at least 3 antihypertensive medications with no changes for 2 weeks before enrollment.

You may not qualify if…

Estimated glomerular filtration rate of less than 30 mL/min per 1.73m2.
Type 1 diabetes mellitus.
History of aortic pathologies such as aneurysm or dissection confirmed by immediate preprocedural angiography that would preclude the Endovascular Denervation (EDN) procedure.
Orthostatic hypotension.
Acute or severe systemic infection.
History of myocardial infarction, unstable angina, or cerebrovascular accident in the previous 3 months.
History of previous renal artery CDN.
Pregnancy or planned pregnancy during the study period.
Unable to provide informed consent.

Where it is running

East Jefferson General Hospital — New Orleans, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.